A patient information leaflet should be supplied to every patient when a systemic corticosteroid is prescribed.
Steroid Treatment Cards should be issued where appropriate to support communication of the risks associated with treatment and to record details of the prescriber, drug, dosage, and duration of treatment.
Steroid Emergency Cards should be issued to patients with adrenal insufficiency and steroid dependence for whom missed doses, illness, or surgery puts them at risk of adrenal crisis.
For further detailed information see https://bnf.nice.org.uk/drugs/prednisolone/.
Betamethasone soluble tablets |
Formulary
|
Soluble tablets 500micrograms |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Dexamethasone |
Formulary
|
Tablets 500micrograms, 2mg |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Hydrocortisone tablets |
Formulary
|
Tablets 10mg, 20mg |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Prednisolone |
Formulary
|
Tablets 1mg, 5mg
|
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Betamethasone injection |
Formulary
|
Injection 4mg/1mL |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Deflazacort |
Formulary
|
Should only be used for patients in whom oral prednisolone is not tolerated due to cushingoid side effects. |
![]() ![]() ![]() ![]() ![]() ![]() |
Hydrocortisone Alkindi® |
Formulary
|
Granules in capsules for opening 0.5mg, 1mg, 2mg For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old) Add following Wording: For the treatment of infants and children (birth to < 18 years) with adrenal insufficiency receiving divided doses of < 5 mg for whom hydrocortisone must otherwise be individually prepared by manipulation such as by compounding (or crushing) or by production of special solutions in order to produce age-appropriate doses, or hydrocortisone given as off-label buccal tablets. The dose of hydrocortisone and the patient’s clinical condition should have been stabilised and reviewed prior to prescribing responsibility passing to primary care clinicians. |
![]() ![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Hydrocortisone MR capsules Efmody |
Formulary
|
Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. For the 2nd line treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over, and adults, in the following circumstances: Patients showing signs of excess steroid replacement with alternative preparations such as prednisolone and hydrocortisone |
![]() ![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Hydrocortisone sodium phosphate Efcortesol® |
Formulary
|
Injection 100mg/1mL |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
Hydrocortisone sodium succinate Solu-Cortef® |
Formulary
|
Injection 100mg vial |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |